Trials / Withdrawn
WithdrawnNCT03632317
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 2 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (stratum A) and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panobinostat | 30 mg/m\^2 |
| DRUG | Everolimus | 3.0 mg/m\^2 |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
- First posted
- 2018-08-15
- Last updated
- 2019-08-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03632317. Inclusion in this directory is not an endorsement.